Intramuscular Injectable Generic Analgesic Ketamine for use in an FDA Approved Emergency... Tender

DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA) has floated a tender for Intramuscular Injectable Generic Analgesic Ketamine for use in an FDA Approved Emergency Use Authorization. The project location is USA and the tender is closing on 07 Oct 2024. The tender notice number is HT9425-24-RFI-TJK3, while the TOT Ref Number is 106901307. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : USA

Summary : Intramuscular Injectable Generic Analgesic Ketamine for use in an FDA Approved Emergency Use Authorization

Deadline : 07 Oct 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 106901307

Document Ref. No. : HT9425-24-RFI-TJK3

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

The purpose of this RFI is to address the USAMMDA WPAC requirement for the development of analgesics for acute severe pain associated with battlefield injuries. The WPAC PMO of USAMMDA is conducting market research to determine the feasibility of securing a manufacturer for the procurement of generic ready-to-inject ketamine for intramuscular injection (IM) for analgesia. No other route of ketamine administration or combination product(s), including autoinjectors, will be considered. In addition, the injectable ketamine must be available for immediate purchase from the open market. The generic ketamine will be used to gain an FDA approved Emergency Use Authorization (EUA) for analgesic ketamine with a subsequent proposed label indication for acute pain via the 505(b)(2) pathway. The sponsor for the EUA will be the Department of Defense (DoD). The analgesic ketamine EUA will allow the DoD to formulate policies on analgesic ketamine use which is expected to result in a large demand for ketamine throughout the Joint Service Military Health System.
Active Contract Opportunity
Notice ID : HT9425-24-RFI-TJK3
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: ARMY MED RES ACQ ACTIVITY
General Information
Contract Opportunity Type: Sources Sought (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Sep 06, 2024 01:33 pm EDT
Original Response Date: Oct 07, 2024 05:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Oct 22, 2024
Initiative: None

Classification
Original Set Aside:
Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; ExPERIMENTAL DEVELOPMENT
NAICS Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance: Frederick, MD 21702 USA

Documents

 Tender Notice

HT9425-24-RFI-TJK3-RFI.docx


Procurement Documents for USA

Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA

Explore Procurement Documents for USA


Want To Bid in This Tender?

Get Local Agent Support in USA and 60 More Countries.

View All The Services


View Tenders By


Publish Tenders


Have Any Dispute With The Purchaser?